Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) shares traded down 0.7% during trading on Thursday . The stock traded as low as $1.42 and last traded at $1.45. 24,672 shares were traded during trading, a decline of 81% from the average session volume of 132,445 shares. The stock had previously closed at $1.46.
Analyst Ratings Changes
A number of equities research analysts have commented on IKNA shares. Wedbush reiterated a "neutral" rating and issued a $2.00 price target on shares of Ikena Oncology in a research report on Monday, December 23rd. HC Wainwright reiterated a "buy" rating and issued a $4.00 target price on shares of Ikena Oncology in a report on Monday, November 11th.
Check Out Our Latest Research Report on Ikena Oncology
Ikena Oncology Price Performance
The firm has a market cap of $69.98 million, a price-to-earnings ratio of -1.18 and a beta of 0.48. The firm's fifty day moving average is $1.57 and its 200-day moving average is $1.66.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.08. As a group, equities research analysts anticipate that Ikena Oncology, Inc. will post -0.91 EPS for the current year.
Institutional Investors Weigh In On Ikena Oncology
A number of large investors have recently bought and sold shares of the stock. BML Capital Management LLC boosted its position in shares of Ikena Oncology by 395.8% during the 4th quarter. BML Capital Management LLC now owns 3,585,866 shares of the company's stock worth $5,881,000 after purchasing an additional 2,862,578 shares in the last quarter. NEA Management Company LLC raised its stake in Ikena Oncology by 5.3% during the 3rd quarter. NEA Management Company LLC now owns 600,063 shares of the company's stock worth $1,038,000 after buying an additional 30,013 shares during the period. Peapod Lane Capital LLC bought a new position in Ikena Oncology in the fourth quarter worth approximately $833,000. Geode Capital Management LLC grew its stake in Ikena Oncology by 5.6% in the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company's stock valued at $469,000 after acquiring an additional 14,319 shares during the period. Finally, BBR Partners LLC increased its holdings in shares of Ikena Oncology by 550.0% during the third quarter. BBR Partners LLC now owns 130,000 shares of the company's stock valued at $225,000 after acquiring an additional 110,000 shares in the last quarter. 75.00% of the stock is currently owned by institutional investors and hedge funds.
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Further Reading
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
